These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29610282)

  • 1. SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules.
    Wang F; Zheng L; Yi Y; Yang Z; Qiu Q; Wang X; Yan W; Bai P; Yang J; Li D; Pei H; Niu T; Ye H; Nie C; Hu Y; Yang S; Wei Y; Chen L
    Mol Cancer Ther; 2018 Apr; 17(4):763-775. PubMed ID: 29610282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SKLB-14b, a novel oral microtubule-destabilizing agent based on hydroxamic acid with potent anti-tumor and anti-multidrug resistance activities.
    Zhang W; Yang L; Si W; Tang M; Bai P; Zhu Z; Kuang S; Liu J; Shi M; Huang J; Chen X; Li D; Wen Y; Yang Z; Xiao K; Chen L
    Bioorg Chem; 2022 Nov; 128():106053. PubMed ID: 35964504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
    Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
    J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Methylquinazoline derivative 23BB as a highly selective histone deacetylase 6 inhibitor alleviated cisplatin-induced acute kidney injury.
    Hao Y; Guo F; Huang Z; Feng Y; Xia Z; Liu J; Li L; Huang R; Lin L; Ma L; Fu P
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
    Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
    Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
    Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
    Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
    Van Helleputte L; Kater M; Cook DP; Eykens C; Rossaert E; Haeck W; Jaspers T; Geens N; Vanden Berghe P; Gysemans C; Mathieu C; Robberecht W; Van Damme P; Cavaletti G; Jarpe M; Van Den Bosch L
    Neurobiol Dis; 2018 Mar; 111():59-69. PubMed ID: 29197621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Histone Deacetylase 6 Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress and Apoptosis.
    Feng Y; Huang R; Guo F; Liang Y; Xiang J; Lei S; Shi M; Li L; Liu J; Feng Y; Ma L; Fu P
    Front Pharmacol; 2018; 9():274. PubMed ID: 29632491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer.
    Chen J; Sang Z; Jiang Y; Yang C; He L
    Chem Biol Drug Des; 2019 Mar; 93(3):232-241. PubMed ID: 30251407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
    Wang F; Zhong BW; Zhao ZR
    J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
    Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D
    Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition.
    Bertels Z; Singh H; Dripps I; Siegersma K; Tipton AF; Witkowski WD; Sheets Z; Shah P; Conway C; Mangutov E; Ao M; Petukhova V; Karumudi B; Petukhov PA; Baca SM; Rasenick MM; Pradhan AA
    Elife; 2021 Apr; 10():. PubMed ID: 33856345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
    Huang Z; Xia Y; Hu K; Zeng S; Wu L; Liu S; Zhi C; Lai M; Chen D; Xie L; Yuan Z
    J Neurochem; 2020 Jan; 152(2):221-234. PubMed ID: 31390677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.
    Yan J; Zhuang Q; Li Z; Xiong Y; He M; Kang C; Zhang Q; Han L; Liang E; Liu H; Ke P; Huang X
    Eur J Pharmacol; 2021 May; 898():173975. PubMed ID: 33647258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
    Liu JR; Yu CW; Hung PY; Hsin LW; Chern JW
    Biochem Pharmacol; 2019 May; 163():458-471. PubMed ID: 30885763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
    Kaliszczak M; Trousil S; Åberg O; Perumal M; Nguyen QD; Aboagye EO
    Br J Cancer; 2013 Feb; 108(2):342-50. PubMed ID: 23322205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.